Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3413994 | 0.88 | HTR2C (1.00) | HTR2CHTR2BDRD2HTR2A | |
| Hydrochloric Acid SCHEMBL4512966 | 0.87 | HTR2C (0.97) | HTR2CHTR2BDRD2HTR2A | |
| SCHEMBL34460267 | 0.82 | HTR2C (1.00) | HTR2CHTR2BOPRD1OPRK1KCNH2 | |
| SCHEMBL468604 | 0.78 | HTR2C (1.00) | HTR2CHTR2BOPRD1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL3226116 | 0.76 | HTR2C (0.97) | HTR2CHTR2BOPRD1OPRK1KCNH2 | |
| Butane SCHEMBL8573679 | 0.75 | HTR2C (0.85) | HTR2CHTR2BOPRD1OPRK1KCNH2 | |
| SCHEMBL31235894 | 0.74 | HTR2C (0.81) | HTR2CHTR2BDRD2HTR2AOPRD1 | |
| SCHEMBL20270447 | 0.74 | HTR2C (0.81) | HTR2CHTR2BDRD2HTR2AOPRD1 | |
| SCHEMBL3411611 | 0.73 | HTR2C (0.69) | HTR2CHTR2BOPRD1OPRK1KCNH2 | |
| SCHEMBL23957147 | 0.72 | HTR2C (0.73) | HTR2CHTR2BDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414366-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | Novartis AG (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2010112520-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010135-A1 | SPIRO DERIVATIVES FOR THE MODULATION OF STEAROYL-COA DESATURASE | SCD, SCD5, FADS2 | HTR2C 3206/4885HTR2B 4016/4885DRD2 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.